(Q37458175)

20 August 2017

1 reference

title

Molecular therapy in head and neck oncology (English)

1 reference

20 August 2017

Jacques Bernier

1

1 reference

20 August 2017

Søren M Bentzen

series ordinal

2

1 reference

20 August 2017

Jan B Vermorken

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

Nature Reviews Clinical Oncology

20 August 2017

1 reference

20 August 2017

6

1 reference

20 August 2017

5

1 reference

20 August 2017

266-277

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2009.40

20 August 2017

0 references

cites work

Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Increasing Toxicity in Nonoperative Head and Neck Cancer Treatment: Investigations and Interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Evaluation of early and late toxicities in chemoradiation trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Untangling the ErbB signalling network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Epidermal growth factor receptor directed therapy in head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Integration of EGFR inhibitors with radiochemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Amplification of ERBB oncogenes in squamous cell carcinomas of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

TGF-alpha and EGF-receptor mRNAs in human oral cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Epidermal growth factor receptor family and chemosensitization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Differential expression of epidermal growth factor receptor in human head and neck cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

The EGFR as a target for anticancer therapy--focus on cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Tumor response to radiotherapy regulated by endothelial cell apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Antiepidermal growth factor receptor antibodies augment cytotoxicity of chemotherapeutic agents on squamous cell carcinoma cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Platinum-based chemotherapy plus cetuximab in head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Panitumumab: in the treatment of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa")

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

The epidermal growth factor receptor and its inhibition in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Mismatch repair gene expression and genetic instability in testicular germ cell tumor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Mechanisms of cutaneous toxicities to EGFR inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Recombinant toxin DAB389EGF is cytotoxic to human pancreatic cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Cimetidine inhibits epidermal growth factor-induced cell signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.40

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

31 March 2020

1 reference

12 December 2020

Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell

1 reference

12 December 2020

Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis

1 reference

12 December 2020

Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy

1 reference

12 December 2020

Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

1 reference

12 December 2020

Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xeno

1 reference

12 December 2020

Mutational analysis of K-ras and Ras protein expression in larynx squamous cell carcinoma.

1 reference

12 December 2020

Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice

1 reference

12 December 2020

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation

1 reference

12 December 2020

Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function

1 reference

12 December 2020

The EGF receptor - an essential regulator of multiple epidermal functions

1 reference

12 December 2020

Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts

1 reference

12 December 2020

Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial.

1 reference

12 December 2020

Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler

1 reference

12 December 2020

Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade.

1 reference

12 December 2020

Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors

1 reference

12 December 2020

Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model

1 reference

12 December 2020

In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody

1 reference

12 December 2020

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

1 reference

12 December 2020

Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells

1 reference

12 December 2020

Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation

1 reference

12 December 2020

ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.

1 reference

12 December 2020

Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis

1 reference

12 December 2020

Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145.

1 reference

12 December 2020

Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas

1 reference

12 December 2020

Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism.

1 reference

12 December 2020

Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors

1 reference

12 December 2020

Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

1 reference

12 December 2020

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

1 reference

12 December 2020

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions

1 reference

12 December 2020

Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice

1 reference

12 December 2020

Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers

1 reference

12 December 2020

10.1038/NRCLINONC.2009.40

Identifiers

DOI

1 reference

Dimensions Publication ID

20 August 2017

0 references

1 reference